CALDERWOOD & HARKNESS LLP
PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
This memorandum is protected by the attorney-client privilege, the work product doctrine, and any other applicable privilege or protection. It is intended solely for use by the attorneys and partners of Calderwood & Harkness LLP in connection with the firm's representation of Whitmore Aerospace LLC. Any disclosure, copying, or distribution of this memorandum, or the information contained herein, to any person not authorized to receive it is strictly prohibited.
MEMORANDUM
TO: Theodore Langston, Partner Vivienne St. Claire, Partner
FROM: Simone Laroche, Senior Associate
DATE: April 15, 2024
RE: Closing Memorandum — Defense of Whitmore Aerospace LLC in ICC Arbitration, Case No. 27914/MHM; Engagement No. 1019-00001
SUBJECT: Case Summary, Key Strategic Decisions, Financial Results, and Lessons Learned
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
This memorandum documents the complete arc of Calderwood & Harkness LLP's ("C&H") engagement in the defense of Whitmore Aerospace LLC ("WAL") in ICC Arbitration Case No. 27914/MHM, from initial retention through the issuance of the Partial Award on March 22, 2024. Its purpose is to capture the key strategic decisions made throughout the engagement, summarize hearing outcomes and the Tribunal's findings, present the financial results achieved for the client, and record lessons learned for the firm's institutional knowledge base. This memorandum should be retained in the engagement file and made available to the firm's practice groups for reference in future international arbitration and commercial dispute engagements.
The Client. Whitmore Aerospace LLC ("WAL") is a Delaware limited liability company headquartered at 4200 Wilson Boulevard, Suite 1100, Arlington, Virginia 22203. WAL is a privately held aerospace and defense manufacturer with annual revenues of approximately $1.87 billion for fiscal year 2022 and approximately 6,400 employees across its domestic and international operations. WAL's primary business lines include the design, manufacture, and supply of turbine components, airframe structural assemblies, and precision-engineered subsystems for both commercial aviation and defense applications.
The Opposing Party. Kestrel Dynamics GmbH ("Kestrel") is a German Gesellschaft mit beschränkter Haftung registered under HRB 745621 at the Amtsgericht Stuttgart, with its principal offices at Industriestraße 88, 70565 Stuttgart, Germany. Kestrel is a precision-components supplier specializing in titanium and nickel-alloy castings and forgings for the aerospace sector. Kestrel reported annual revenues of approximately €312 million for fiscal year 2022.
Nature of the Dispute. The arbitration arose from Kestrel's allegations that WAL materially breached the Master Supply Agreement for Titanium Alloy Turbine Housings dated June 15, 2018 (reference WAL-KDG-MSA-2018-0615) (the "MSA"). Kestrel initiated ICC arbitration proceedings on November 7, 2022, seeking approximately €47.3 million in damages across four categories: lost profits for the remaining contract term, lost profits for the renewal terms, unreimbursed rework costs, and reputational damages. WAL denied all of Kestrel's claims and asserted a counterclaim in the amount of €5.17 million, representing the incremental cost WAL incurred in sourcing replacement titanium alloy turbine housings from an alternative supplier following WAL's termination of the MSA for cause.
Outcome. The Tribunal issued a Partial Award on March 22, 2024, delivering a comprehensive favorable result for WAL. All of Kestrel's claims were dismissed in their entirety. WAL was awarded €3.82 million on its counterclaim (reflecting a 26% mitigation-related reduction from the €5.17 million claimed). Kestrel was ordered to bear 75% of ICC administrative costs and arbitrators' fees (totaling $930,000 of the $1.24 million in total costs) and to reimburse WAL $1.85 million of its legal costs.
Net Financial Outcome for WAL. The net financial outcome for WAL is as follows: a €3.82 million counterclaim recovery, a $1.85 million legal cost reimbursement, and the complete avoidance of approximately €47.3 million in claimed exposure. The total value preserved and recovered for the client is approximately €51.1 million.
Matter Status. The matter is closed. The Partial Award reserved jurisdiction over post-award interest calculations and any disputes regarding enforcement, to be addressed in a Final Award if needed. As of the date of this memorandum, no further proceedings have been initiated, and Kestrel has not indicated an intention to challenge the Partial Award. The engagement should be marked as closed in the firm's matter management system.
II. ENGAGEMENT OVERVIEW
A. Retention and Staffing
Calderwood & Harkness LLP was retained to represent WAL in connection with the anticipated ICC arbitration proceedings pursuant to an engagement letter dated November 2, 2022, addressed to Dana Prescott, Vice President and General Counsel of WAL. The engagement was assigned Engagement Number 1019-00001 in the firm's matter management system.
The engagement team was staffed as follows:
The fee arrangement was structured as straight hourly billing with no contingency component, success fee, or alternative fee structure. All fees were billed monthly, with payment terms of thirty days net. WAL paid all invoices in a timely manner throughout the engagement, and no collection issues arose.
B. Opposing Counsel
Kestrel was represented throughout the arbitration by Haber Reinhardt Schlosser Partnerschaft mbB ("HRS"), operating out of its Stuttgart and London offices. The lead partner on the matter was Dr. Maximilian Haber, an established international arbitration specialist based in HRS's London office. Dr. Haber was supported by Katrin Schäfer, a Senior Associate in HRS's Stuttgart office, who served as associate counsel and handled much of the day-to-day briefing and document production work. HRS is a well-regarded boutique firm with a strong reputation in German and international commercial arbitration, and Dr. Haber proved to be a capable and well-prepared adversary throughout the proceedings.
C. Key Client Contacts
The following individuals at WAL served as key points of contact during the engagement:
• Dana Prescott, Vice President and General Counsel — Ms. Prescott served as the primary point of contact throughout the engagement. She was responsible for coordinating document collection, arranging witness access, and serving as the liaison between the C&H engagement team and WAL's executive leadership. Ms. Prescott was responsive, well-organized, and deeply familiar with the MSA and the underlying commercial relationship with Kestrel.
• Marcus J. Whitmore III, Chief Executive Officer — Mr. Whitmore was engaged for strategic decisions at key junctures and received periodic briefings on the progress of the arbitration. He was particularly involved in the decision to pursue the counterclaim strategy and received a detailed post-hearing report prior to the issuance of the Partial Award.
• Gerald Huang, Vice President, Global Supply Chain Operations — Mr. Huang served as a key fact witness on matters relating to the procurement process, the lot rejection history, the onboarding of Valkyr Precision Components Inc. as a replacement supplier, and the operational impact of Kestrel's quality failures on WAL's manufacturing operations.
• Dr. Ingrid Vollmer, Senior Vice President, Engineering and Manufacturing — Dr. Vollmer served as a key fact witness on matters relating to WAL's quality-control processes, the porosity specifications set forth in WAL-SPEC-TH-401, and the engineering rationale for the contractual tolerance levels. Dr. Vollmer's testimony was precise, technically authoritative, and highly effective at the evidentiary hearing.
D. Third-Party Engagements
The following third-party experts and consultants were engaged to support WAL's defense and counterclaim:
Damages and Quantum Expert. Dr. Nadia Ostrovsky, Managing Director, Ridgeline Economic Consulting LLC, 200 Park Avenue, Suite 3400, New York, New York 10166. Dr. Ostrovsky was retained as WAL's damages and quantum expert. She provided a comprehensive report challenging the damages methodology employed by Kestrel's expert, Prof. Langfeld, and presented a detailed analysis of the proper measure of WAL's counterclaim damages. Dr. Ostrovsky's engagement letter was executed in March 2023, and she provided both an initial expert report and a rebuttal report.
Metallurgical and Technical Expert. Dr. Raymond Chow, Principal Engineer, Arclight Materials Science Inc., 7900 Westpark Drive, Suite 200, McLean, Virginia 22102. Dr. Chow was retained as WAL's metallurgical and technical expert. He conducted independent porosity testing of samples from the rejected lots and provided expert testimony confirming that porosity levels in the rejected lots ranged from 0.19% to 0.38%, exceeding the contractual specification of ≤0.25%. Dr. Chow's testing methodology adhered to recognized ASTM standards and AS9100 Rev D protocols, which proved to be a significant advantage at the hearing.
Forensic Accounting Support. Sandra Gillespie, CPA/ABV, Canfield & Thorpe LLP, 1345 Avenue of the Americas, New York, New York 10105. Ms. Gillespie was retained to provide forensic accounting review and analysis of Kestrel's lost-profit damages claims, with particular focus on the margin assumptions underpinning Prof. Langfeld's damages model. Ms. Gillespie's analysis corroborated Dr. Ostrovsky's critique of the inflated 22.4% margin figure used by Kestrel's expert.
Insurance Notification. Pinnacle Continental Insurance Co. was notified of the arbitration under Policy No. PCE-GL-2021-08854 on November 14, 2022. A coverage reservation letter was received from Pinnacle Continental's coverage counsel shortly thereafter. Pinnacle Continental ultimately declined to provide a defense or indemnity under the policy, citing the commercial-supply exclusion applicable to disputes arising from the sale or supply of goods under a commercial contract. This determination was not unexpected, but the early notification preserved WAL's rights under the policy and ensured compliance with the policy's notice provisions.
Lender Notification and Covenant Monitoring. Throughout the engagement, C&H and WAL's in-house counsel monitored the potential covenant compliance implications of the arbitration with respect to Veltrano National Bank, N.A., WAL's senior secured lender under a $350 million revolving credit facility. The credit agreement contained financial covenants and reporting obligations that could potentially have been triggered by an adverse arbitration outcome of the magnitude claimed by Kestrel. WAL provided periodic updates to Veltrano as required under the credit agreement's litigation reporting provisions. No covenant trigger resulted from the arbitration, and the favorable outcome of the Partial Award eliminated any residual risk to the facility.
III. FACTUAL BACKGROUND AND CONTRACTUAL FRAMEWORK
A. The Master Supply Agreement
The Master Supply Agreement for Titanium Alloy Turbine Housings (reference WAL-KDG-MSA-2018-0615) (the "MSA") was executed on June 15, 2018, between WAL, as Buyer, and Kestrel, as Seller. The MSA established the framework for Kestrel's manufacture and supply of Ti-6Al-4V ELI (Extra Low Interstitials) titanium alloy turbine housings in accordance with WAL's proprietary engineering specifications designated WAL-SPEC-TH-401 through WAL-SPEC-TH-409. These housings are critical structural components used in turbine engine assemblies manufactured by WAL for both commercial and military aviation applications.
The key commercial terms of the MSA were as follows:
Term. The MSA had a five-year initial term commencing on June 15, 2018, and expiring on June 14, 2023. The MSA provided for two optional one-year renewal periods, each exercisable solely at WAL's discretion upon written notice delivered not less than ninety days prior to the expiration of the then-current term. Neither renewal option was exercised prior to WAL's termination of the MSA for cause.
Volume Commitment. The MSA established an annual volume commitment of a minimum of 2,400 units and a maximum of 3,600 units. This volume range was subsequently increased by Amendment No. 1 (discussed below) to a maximum of 4,000 units.
Pricing. The base unit price for Contract Year 1 was set at €4,850.00 per unit, subject to an annual escalation of 2.5% compounded. The resulting unit prices for each contract year were as follows:
At the minimum annual volume of 2,400 units, the aggregate contract value over the five-year initial term was approximately €61.2 million.
Delivery Terms. All deliveries were to be made DDP (Delivered Duty Paid) to WAL's manufacturing facility located at 8500 Coppermine Road, Manassas, Virginia 20110, in accordance with Incoterms 2020. Kestrel bore all transportation costs, duties, and risk of loss until delivery at WAL's facility.
Quality Standards. The MSA required Kestrel to maintain AS9100 Rev D certification throughout the term and to manufacture all turbine housings in conformance with the technical specifications set forth in WAL-SPEC-TH-401 through WAL-SPEC-TH-409. Upon delivery, WAL was entitled to conduct incoming inspection in accordance with its quality-control procedure WAL-QCP-100, with an acceptance or rejection determination to be made within fifteen business days of receipt.
Governing Law. Section 22.1 of the MSA specified that the agreement would be governed by and construed in accordance with the laws of the State of New York, without regard to its conflict-of-laws provisions.
Dispute Resolution. Section 22.3 of the MSA provided for resolution of any disputes arising out of or in connection with the agreement under the ICC Rules of Arbitration (2021 edition), to be conducted before a three-member tribunal with its seat in New York, New York.
B. Key Contractual Provisions
Several provisions of the MSA proved to be of central importance to the resolution of the dispute. These provisions are summarized below and were the subject of extensive briefing and argument before the Tribunal.
Section 8.4 — Rejection and Cure. Section 8.4 of the MSA established the framework for lot rejections and the Seller's right to cure. Under this provision, if WAL rejected a lot for non-conformance with the applicable engineering specifications, Kestrel was afforded a period of thirty calendar days (subsequently extended to forty-five calendar days by Amendment No. 2) to cure the deficiency by either replacing the non-conforming units or reworking them to meet the required specifications. Critically, Section 8.4 further provided that three or more uncured rejections occurring within any rolling twelve-month period would constitute a "Persistent Quality Failure" — a defined term with significant consequences under the termination provisions of the MSA.
Section 8.7 — Exclusive Remedy and Consequential Damages Waiver. Section 8.7 established the exclusive remedies available to WAL in the event of non-conformance: replacement of defective units, credit against future orders, or termination of the MSA upon the occurrence of a Persistent Quality Failure. Importantly, Section 8.7 included a mutual waiver of consequential damages, including but not limited to lost profits, loss of use, loss of revenue, and reputational harm. This waiver proved to be one of the most consequential provisions in the entire agreement, as discussed further in Section VI below.
Section 14.2 — Termination for Cause. Section 14.2 set forth two independent bases for termination for cause: (a) material breach that remains uncured for sixty days following delivery of written notice specifying the breach; or (b) the occurrence of a Persistent Quality Failure as defined in Section 8.4. WAL's termination was predicated on Section 14.2(b), the Persistent Quality Failure ground.
Porosity Specification. The contractual porosity specification — the single most contested factual issue in the arbitration — was set forth in WAL-SPEC-TH-401, Appendix C, Table 3. That specification established a maximum allowable porosity level of ≤0.25% for all Ti-6Al-4V ELI turbine housing castings delivered under the MSA. This threshold is consistent with aerospace industry norms for structural turbine components and was expressly incorporated by reference into the MSA.
C. Amendments. The MSA was amended twice during the term of the agreement:
Amendment No. 1 (February 10, 2020). Amendment No. 1 added WAL-SPEC-TH-410, a new engineering specification for a high-temperature variant of the Ti-6Al-4V ELI turbine housing designed for next-generation engine applications. Amendment No. 1 also increased the maximum annual volume commitment from 3,600 units to 4,000 units to accommodate anticipated demand for the high-temperature variant. All other terms of the MSA remained unchanged.
Amendment No. 2 (September 3, 2021). Amendment No. 2 was negotiated in response to significant supply-chain disruptions caused by the COVID-19 pandemic. The amendment extended the cure period under Section 8.4 from thirty calendar days to forty-five calendar days, reflecting the reality that replacement and rework timelines had been materially impacted by logistics delays, shipping constraints, and workforce availability issues. Amendment No. 2 also added a force majeure carve-out specifically addressing pandemic-related delays in delivery schedules. Importantly — and as discussed further in Section VIII.C below — Amendment No. 2 did not modify the quality standards, engineering specifications, or porosity tolerances applicable to the turbine housings.
D. The Quality Failures and Termination
The quality failures that gave rise to the termination and the subsequent arbitration occurred over a period of approximately six months, from March through September 2022. During this period, WAL's incoming inspection process under WAL-QCP-100 identified systemic non-conformance in Kestrel's deliveries, specifically with respect to porosity levels exceeding the ≤0.25% contractual threshold.
Between March 7, 2022 (Lot KDG-2022-0307, the first rejected lot) and September 19, 2022 (Lot KDG-2022-0919, the seventh and final uncured rejection), WAL rejected a total of fourteen lots encompassing 1,680 individual turbine housing units. Each rejection was documented in accordance with WAL-QCP-100, with detailed porosity measurements recorded for each sampled unit within the lot.
To independently verify WAL's internal inspection findings, Arclight Materials Science Inc. conducted metallurgical testing of retained samples from the rejected lots. Dr. Raymond Chow's analysis confirmed porosity levels ranging from 0.19% to 0.38% across the rejected lots. While some units in certain lots fell within the ≤0.25% specification, the lot-level measurements demonstrated that the lots as a whole failed to meet the contractual standard, with numerous individual units exhibiting porosity well in excess of the 0.25% threshold.
Of the fourteen rejected lots, seven remained uncured after the expiration of the forty-five calendar day cure period established by Amendment No. 2. This far exceeded the three-uncured-rejection threshold required to constitute a Persistent Quality Failure under Section 8.4 of the MSA.
On October 3, 2022, WAL issued a formal Notice of Termination for Cause to Kestrel, invoking Section 14.2(b) of the MSA on the basis of Persistent Quality Failure. The Notice of Termination was delivered by both international courier and electronic mail to Kestrel's designated notice address and its General Counsel's office. The notice identified each of the seven uncured rejections by lot number, referenced the applicable porosity test results, and stated WAL's position that the Persistent Quality Failure threshold had been met and exceeded.
Following termination, WAL engaged Valkyr Precision Components Inc., a precision aerospace components manufacturer based in Tucson, Arizona, as a replacement supplier for the Ti-6Al-4V ELI turbine housings. Valkyr's unit price was €8,432.92, subject to a 4.2% introductory discount, resulting in an effective unit price substantially higher than the Kestrel CY4 price of €5,222.92. The incremental cost of sourcing from Valkyr formed the basis of WAL's counterclaim.
IV. PROCEDURAL HISTORY
A. Pre-Arbitration Steps
The procedural sequence of events leading up to the commencement of the arbitration is summarized as follows:
• October 3, 2022: WAL issued its Notice of Termination for Cause to Kestrel, invoking Section 14.2(b) of the MSA on the basis of Persistent Quality Failure. The notice was prepared by WAL's in-house legal team and delivered to Kestrel at its registered address in Stuttgart.
• November 1, 2022: C&H completed its conflict check in connection with the prospective engagement. No conflicts were identified with Kestrel, HRS, or any related parties. The conflict check encompassed all C&H offices and covered both current and former client relationships and any adverse-interest issues.
• November 2, 2022: The engagement letter was executed by Dana Prescott, VP and General Counsel of WAL, formalizing C&H's retention as counsel of record for WAL in connection with the anticipated ICC arbitration proceedings.
• November 7, 2022: Kestrel filed its Request for Arbitration with the International Chamber of Commerce, and the matter was assigned Case No. 27914/MHM. The Request for Arbitration set forth Kestrel's claims in summary form, alleging that WAL had materially breached the MSA by wrongfully rejecting conforming lots and improperly terminating the agreement, and seeking approximately €47.3 million in damages.
• November 8, 2022: A litigation hold notice was issued by Simone Laroche to Dana Prescott and Gerald Huang at WAL, directing the immediate preservation of all documents relating to the MSA, including but not limited to lot inspection records, WAL-QCP-100 quality-control reports, engineering specifications WAL-SPEC-TH-401 through WAL-SPEC-TH-410, all correspondence with Kestrel, purchase orders, shipping and receiving records, and any internal communications relating to the Kestrel supply relationship. The litigation hold notice was subsequently distributed by Ms. Prescott to all relevant WAL personnel, including the engineering, manufacturing, quality assurance, and procurement departments.
• November 14, 2022: Notification of the arbitration was sent to Pinnacle Continental Insurance Co. under Policy No. PCE-GL-2021-08854, in accordance with the policy's notice provisions. As noted in Section II.D above, Pinnacle Continental subsequently issued a coverage reservation letter and ultimately declined coverage under the commercial-supply exclusion.
B. Arbitral Proceedings
The arbitral proceedings unfolded over a period of approximately sixteen months from the filing of the Request for Arbitration through the issuance of the Partial Award. The key procedural milestones are set forth below in chronological order:
• December 12, 2022: WAL filed its Answer to the Request for Arbitration and its Counterclaim. The Answer denied all of Kestrel's allegations of material breach and asserted that WAL's termination was proper under Section 14.2(b) of the MSA. The Counterclaim sought €5.17 million in damages, representing the incremental cost incurred by WAL in sourcing replacement turbine housings from Valkyr Precision Components Inc.
• December 19, 2022: WAL nominated the Honorable Robert A. Castillo (retired judge of the United States District Court for the Southern District of New York) as its co-arbitrator. Judge Castillo was selected for his extensive commercial-contract expertise and his deep familiarity with New York law, which was the governing law of the MSA.
• January 20, 2023: The Tribunal was constituted. The three members of the Tribunal were:
• Presiding Arbitrator: Professor Dame Eleanor Fitzwilliam, appointed by agreement of the parties. Prof. Fitzwilliam is a highly regarded figure in international commercial arbitration, known for her balanced and rigorous approach to procedural management and decision-making.
• Claimant's Co-Arbitrator: Dr. Hans-Ulrich Perren, a former judge of the Swiss Federal Supreme Court, nominated by Kestrel.
• Respondent's Co-Arbitrator: Honorable Robert A. Castillo, a retired judge of the United States District Court for the Southern District of New York, nominated by WAL.
• February 14, 2023: The Tribunal convened a preliminary procedural conference with the parties to establish the procedural framework for the arbitration. Following the conference, the Tribunal issued Procedural Order No. 1, which set forth the procedural timetable, the rules governing written submissions, document production, expert evidence, and the evidentiary hearing.
• March 2023: C&H executed engagement letters with Dr. Nadia Ostrovsky of Ridgeline Economic Consulting LLC (damages and quantum expert) and Dr. Raymond Chow of Arclight Materials Science Inc. (metallurgical and technical expert). Both experts were briefed on the factual background and provided with relevant documents for their respective analyses.
• March 17, 2023: The Tribunal issued Procedural Order No. 2, which established the document production schedule and addressed the parties' respective document requests. WAL submitted its Redfern Schedule requesting production of Kestrel's internal quality-control records, testing data, production logs, and communications relating to porosity issues in the turbine housings. WAL also filed objections to several of Kestrel's document requests on the grounds that they were overbroad (particularly Kestrel's request for the entirety of WAL's negotiations with Valkyr) and sought materials protected by the attorney-client privilege and the work product doctrine (specifically, WAL's internal supplier diversification strategy communications).
• April 28, 2023: Kestrel filed its Statement of Claim, setting forth in detail its allegations of material breach, the damages it claimed to have suffered, and the legal bases for its claims under New York law and the MSA.
• May 2023: Expert instruction memoranda were provided to Dr. Ostrovsky and Dr. Chow, setting forth the specific issues on which their expert opinions were sought and the parameters within which their analyses were to be conducted. These memoranda were prepared in accordance with the Tribunal's directions regarding expert evidence as set forth in Procedural Order No. 1.
• June 30, 2023: WAL filed its Statement of Defense and Counterclaim, presenting its comprehensive factual narrative and legal arguments in defense of Kestrel's claims and in support of WAL's affirmative counterclaim.
• August 11, 2023: Kestrel filed its Reply and Defense to Counterclaim, responding to WAL's Statement of Defense and setting forth its arguments against the counterclaim.
• September 29, 2023: WAL filed its Rejoinder, addressing the arguments raised in Kestrel's Reply and providing additional responsive materials.
• October 16, 2023: Expert reports were exchanged simultaneously by the parties. On the damages side, Dr. Ostrovsky submitted her report on behalf of WAL, while Prof. Langfeld of Rheinsberg Advisory AG submitted his report on behalf of Kestrel. On the metallurgical side, Dr. Chow submitted his report on behalf of WAL, while Dr. Kessler of Albrecht Prüftechnik GmbH submitted her report on behalf of Kestrel.
• November 13, 2023: Rebuttal expert reports were exchanged. Each party's experts provided responsive analyses addressing the opinions and methodologies set forth in the opposing party's initial expert reports.
• January 8–12, 2024: The evidentiary hearing was conducted over five days at the ICC Hearing Centre in New York, New York. The hearing included opening statements by counsel, direct and cross-examination of fact witnesses, presentation and examination of expert witnesses, and closing arguments. A detailed summary of the hearing proceedings is provided in Section V.F below.
• February 9, 2024: Post-hearing briefs were filed simultaneously by both parties, summarizing the evidence presented at the hearing, addressing key factual and legal issues, and setting forth each party's final arguments on liability, damages, and costs.
• March 22, 2024: The Tribunal issued the Partial Award. The substance of the Partial Award is discussed in detail in Section VI below.
V. KEY STRATEGIC DECISIONS AND ANALYSIS
This section records the principal strategic decisions made during the course of the engagement, together with the rationale for each decision and, where relevant, an assessment of how each decision contributed to the outcome.
A. Dual-Track Defense Strategy
At the outset of the engagement, the team made the strategic decision to pursue a dual-track approach: a robust substantive defense against Kestrel's breach-of-contract claims, coupled with an affirmative counterclaim seeking recovery of the incremental costs WAL incurred in sourcing replacement turbine housings from Valkyr.
The substantive defense rested on two complementary pillars. First, the lot rejections were substantively justified because the porosity levels in the rejected lots exceeded the ≤0.25% contractual specification, as documented by WAL's incoming inspection records and independently confirmed by Dr. Chow's metallurgical analysis. Second, the termination was procedurally and substantively proper under Section 14.2(b) of the MSA because seven uncured rejections within a rolling twelve-month period far exceeded the three-rejection Persistent Quality Failure threshold established by Section 8.4.
The decision to assert the counterclaim served a strategic purpose beyond the recovery of the €5.17 million in damages sought. By counterclaiming, WAL effectively reframed the dispute narrative before the Tribunal, positioning WAL as the injured party that had been forced to incur substantial additional costs as a direct consequence of Kestrel's quality failures, rather than as a party that had opportunistically terminated a supply agreement. This narrative shift proved valuable throughout the proceedings, particularly at the evidentiary hearing, where it reinforced the theme that Kestrel — not WAL — was the underperforming party.
B. Arbitrator Selection
The selection of the Honorable Robert A. Castillo as WAL's co-arbitrator was a deliberate strategic choice. Judge Castillo served on the bench of the United States District Court for the Southern District of New York for over twenty years before his retirement and brought deep expertise in complex commercial-contract disputes. His familiarity with New York law — the governing law of the MSA — was a significant advantage, particularly on issues relating to the enforceability of the Section 8.7 consequential damages waiver and the interpretation of the termination-for-cause provisions. Judge Castillo's reputation for rigorous analysis of contractual language and fact-intensive disputes made him well-suited to the commercial and technical issues at the core of this case.
The agreement with Kestrel on the appointment of Professor Dame Eleanor Fitzwilliam as Presiding Arbitrator was reached after careful consideration. Prof. Fitzwilliam is widely regarded as one of the leading international commercial arbitration practitioners in the world, known for her balanced and methodical approach to case management and decision-making. While her appointment was a consensus selection, C&H assessed that her procedural rigor and commitment to evidence-based decision-making would favor WAL's position, which was grounded in detailed documentary evidence and rigorous expert analysis. This assessment proved accurate.
C. Document Production Strategy
The document production phase was a critical juncture in the arbitration. C&H pursued an aggressive strategy in seeking production of Kestrel's internal quality records through the Redfern Schedule process, while simultaneously resisting Kestrel's overreaching requests for WAL's privileged and confidential materials.
On the offensive side, C&H's Redfern Schedule requests targeted Kestrel's internal quality-control records, testing protocols, production logs, and internal communications relating to porosity levels in the turbine housings. The Tribunal granted these requests over Kestrel's objections, and the produced documents proved to be among the most consequential evidence in the case. In particular, the production yielded internal Kestrel communications demonstrating that Kestrel's quality-assurance personnel were aware of porosity issues in their casting processes that pre-dated the first rejected lot. These communications directly undermined Kestrel's narrative that WAL had suddenly and unfairly begun applying an unpublished, more stringent porosity standard.
On the defensive side, C&H successfully resisted two significant document requests by Kestrel. First, Kestrel sought production of the entirety of WAL's negotiations with Valkyr Precision Components, including pricing proposals, term sheets, and internal evaluation documents. C&H argued that this request was overbroad and disproportionate, and that the relevant information — the agreed Valkyr pricing — had already been disclosed in WAL's submissions. The Tribunal agreed and denied the request as to all documents other than the executed Valkyr supply agreement and the pricing schedule. Second, Kestrel sought production of WAL's internal communications regarding supplier diversification strategy. C&H objected on grounds of attorney-client privilege and work product protection, noting that several of the responsive communications involved legal advice provided by WAL's in-house counsel in the context of the anticipated dispute. The Tribunal sustained these objections.
D. Expert Witness Strategy
The expert witness strategy was structured around two distinct tracks: metallurgical and technical testimony, and damages and quantum analysis.
Metallurgical Expert (Dr. Raymond Chow, Arclight Materials Science Inc.). Dr. Chow was engaged to provide independent porosity analysis of retained samples from the fourteen rejected lots. His analysis confirmed porosity levels ranging from 0.19% to 0.38%, with the majority of sampled units exceeding the ≤0.25% contractual threshold specified in WAL-SPEC-TH-401, Appendix C, Table 3. Dr. Chow's testing was conducted in accordance with ASTM E1441 and ASTM E2371 standards for porosity measurement in metallic castings, and his laboratory (Arclight's McLean, Virginia facility) holds ISO 17025 accreditation for metallurgical testing. A critical element of Dr. Chow's testimony was his direct rebuttal of Kestrel's claim that WAL had applied an unpublished, more stringent porosity standard of ≤0.15%. Dr. Chow demonstrated that the ≤0.25% standard is expressly set forth in the contractual specifications and is consistent with established aerospace industry norms for structural titanium alloy components.
Damages Expert (Dr. Nadia Ostrovsky, Ridgeline Economic Consulting LLC). Dr. Ostrovsky was retained to provide a comprehensive analysis of Kestrel's damages claims and to develop WAL's counterclaim damages model. On the defensive side, Dr. Ostrovsky's report challenged the methodology employed by Kestrel's damages expert, Prof. Langfeld of Rheinsberg Advisory AG, on multiple fronts:
(a) Inflated Margin Assumption. Prof. Langfeld assumed a 22.4% gross margin for Kestrel's turbine housing production, based on Kestrel's company-wide gross margins rather than product-specific margins. Dr. Ostrovsky demonstrated that the product-specific gross margin for Ti-6Al-4V ELI turbine housings was materially lower, approximately 14.7%, based on Kestrel's own cost-accounting data produced in discovery.
(b) Improper Inclusion of Renewal-Period Profits. Prof. Langfeld's damages model included €27.15 million in lost profits for the two optional renewal periods, treating these periods as if they were contractual certainties. Dr. Ostrovsky opined that this was improper because the renewal options were exercisable solely at WAL's discretion and gave rise to no legally cognizable expectation interest on Kestrel's part.
(c) Speculative Reputational Damages. Kestrel claimed €3.90 million in reputational damages, asserting that the termination had harmed its standing with other aerospace customers. Dr. Ostrovsky critiqued this claim as speculative and unsupported by any reliable economic evidence, noting the absence of any demonstrable loss of business attributable to the termination.
(d) Failure to Account for Consequential Damages Waiver. Dr. Ostrovsky's report further noted that the entirety of Kestrel's lost-profit and reputational-damage claims constituted consequential damages that were contractually barred by Section 8.7 of the MSA.
Forensic Accounting Support (Sandra Gillespie, Canfield & Thorpe LLP). Ms. Gillespie provided forensic accounting analysis that corroborated Dr. Ostrovsky's findings regarding margin inflation in Prof. Langfeld's damages model. Ms. Gillespie's review of Kestrel's financial records, including product-level cost allocation data and gross margin reports, confirmed that the 22.4% margin figure used by Prof. Langfeld was derived from entity-level financial data that did not accurately reflect the economics of the turbine housing product line.
E. Key Legal Memoranda Prepared
Throughout the engagement, C&H prepared several internal legal memoranda analyzing key issues of law and contractual interpretation. These memoranda informed the strategy for WAL's written submissions and the preparation for the evidentiary hearing:
• Material Breach and Termination Rights Analysis (December 2022). This memorandum analyzed WAL's rights under Section 14.2(b) of the MSA in light of the seven uncured lot rejections. The memorandum concluded that the Persistent Quality Failure threshold had been clearly met and that WAL's termination was procedurally and substantively proper. The memorandum also analyzed potential counterarguments regarding WAL's alleged failure to afford Kestrel adequate opportunity to cure and concluded that they lacked merit in light of the 45-day cure period and the number of uncured rejections.
• New York Law on Consequential Damages Waivers (January 2023). This memorandum surveyed New York case law on the enforceability of mutual consequential damages waivers in commercial contracts between sophisticated parties. The memorandum concluded that under well-established New York precedent, Section 8.7's waiver of consequential damages — including lost profits and reputational harm — was enforceable between WAL and Kestrel as sophisticated commercial entities that had freely negotiated the terms of the MSA at arm's length. The memorandum identified and distinguished potentially adverse authority and concluded that the weight of authority strongly favored enforceability.
• Reputational Damages Recoverability (February 2023). This memorandum specifically addressed the recoverability of Kestrel's €3.90 million reputational damages claim under New York law. The memorandum concluded that the claim was both speculative — unsupported by any concrete evidence of actual reputational harm or loss of business — and contractually barred by the Section 8.7 waiver. The memorandum also noted the general reluctance of New York courts and arbitral tribunals to award damages for reputational harm in commercial-contract disputes absent clear and convincing evidence of actual, quantifiable loss.
• Renewal-Period Lost Profits — Option vs. Obligation Analysis (April 2023). This memorandum analyzed whether Kestrel could recover lost profits for the two optional renewal periods under the MSA. The memorandum concluded that the renewal options were exercisable solely at WAL's discretion, that the MSA expressly stated no renewal obligation existed, and that under New York law, discretionary options do not give rise to expectation damages for the non-exercising party. The memorandum surveyed relevant case law on the distinction between contractual options and obligations and concluded that Kestrel had no legally cognizable expectation interest in the renewal periods.
F. Hearing Execution
The five-day evidentiary hearing was conducted at the ICC Hearing Centre in New York, New York, from January 8 through January 12, 2024. Detailed preparation for the hearing began in earnest in November 2023, following the exchange of rebuttal expert reports.
Witness Presentation. WAL presented two fact witnesses at the hearing: Gerald Huang, VP Global Supply Chain Operations, and Dr. Ingrid Vollmer, SVP Engineering and Manufacturing. Mr. Huang testified regarding the procurement process, the lot rejection history, the operational impact of Kestrel's quality failures on WAL's manufacturing operations, and the process by which Valkyr was onboarded as a replacement supplier. Dr. Vollmer testified regarding WAL's quality-control processes, the engineering rationale for the ≤0.25% porosity specification, and the significance of porosity non-conformance in structural turbine components from both a safety and performance standpoint. Both witnesses were thoroughly prepared and delivered clear, consistent, and credible testimony.
Cross-Examination of Kestrel Witnesses. C&H cross-examined three Kestrel fact witnesses: Friedrich Brenner, Luisa Erdmann, and Dr. Stefan Voss.
The cross-examination of Friedrich Brenner proved to be one of the pivotal moments of the hearing. Through careful questioning, Mr. Langston established that Brenner, who served as Kestrel's Head of Quality Assurance, was aware of porosity issues in Kestrel's casting processes that pre-dated the first rejected lot by several months. Brenner's testimony on this point was consistent with the internal Kestrel communications obtained during document production and significantly undermined Kestrel's narrative that the quality failures were isolated anomalies rather than systemic issues.
The cross-examination of Dr. Stefan Voss, Kestrel's VP of Engineering, was equally productive. Dr. Voss had asserted in his witness statement that WAL had applied an "unpublished" porosity standard of ≤0.15% that was more stringent than the contractual specification. Under cross-examination, Dr. Voss was unable to identify any document, communication, or specification supporting this assertion and ultimately acknowledged that the ≤0.25% threshold set forth in WAL-SPEC-TH-401, Appendix C, Table 3 was the operative contractual standard. This concession effectively eliminated one of Kestrel's central defenses.
Expert Witness Examination. Dr. Chow's testimony was particularly effective. His use of industry-standard ASTM testing protocols, his clear and accessible explanation of porosity measurement techniques, and his demonstrated independence and objectivity contributed to the Tribunal's decision to credit his analysis over that of Kestrel's metallurgical expert, Dr. Kessler. An internal review memorandum prepared in November 2023 had identified specific weaknesses in Dr. Kessler's testing methodology — including her reliance on a non-standard testing protocol that deviated from AS9100 Rev D and ASTM standards — and these vulnerabilities were effectively exploited during cross-examination. Dr. Kessler's credibility was further diminished when, under questioning, she acknowledged that her testing protocol had not been validated against the ASTM standards referenced in the contractual specifications.
Dr. Ostrovsky's testimony on damages was equally strong, particularly her critique of Prof. Langfeld's inflated margin assumptions and his inclusion of renewal-period profits in his damages model. Prof. Langfeld's cross-examination revealed that he had not independently verified the product-specific margin data and had relied exclusively on Kestrel's entity-level financial reports.
VI. THE PARTIAL AWARD — MARCH 22, 2024
A. Tribunal's Key Findings
The Tribunal issued its Partial Award on March 22, 2024. The Award was unanimous and addressed all claims and the counterclaim on the merits. The Tribunal's key findings are summarized as follows:
1. WAL Did Not Commit Material Breach of the MSA. The Tribunal found, by a preponderance of the evidence, that the lots rejected by WAL failed to meet the contractual porosity specification of ≤0.25% set forth in WAL-SPEC-TH-401, Appendix C, Table 3. In reaching this conclusion, the Tribunal credited the metallurgical analysis of Dr. Raymond Chow (WAL's expert) over that of Dr. Kessler (Kestrel's expert), finding that Dr. Chow's testing methodology was consistent with recognized industry standards — specifically ASTM E1441 and ASTM E2371 — and that his results were more reliable. The Tribunal noted that Dr. Kessler's reliance on a non-standard testing protocol undermined the reliability of her conclusions. The Tribunal further found that WAL's incoming inspection process under WAL-QCP-100 was conducted properly and in accordance with the MSA's requirements.
2. WAL's Termination for Persistent Quality Failure Was Proper. The Tribunal found that WAL's termination of the MSA for cause under Section 14.2(b) was both procedurally and substantively proper. Seven uncured lot rejections within a rolling twelve-month period exceeded the three-rejection Persistent Quality Failure threshold established by Section 8.4 of the MSA. The Tribunal rejected Kestrel's argument that WAL had failed to afford adequate opportunity to cure, noting that the 45-day amended cure period (as extended by Amendment No. 2) had expired for each of the seven uncured rejections.
3. WAL Did Not Apply Unpublished Specifications. The Tribunal rejected Kestrel's assertion that WAL had applied an unpublished, more stringent porosity standard of ≤0.15%. The Tribunal found that the ≤0.25% standard is expressly stated in WAL-SPEC-TH-401, Appendix C, Table 3, that this standard was incorporated by reference into the MSA, and that no credible evidence supported Kestrel's contention that WAL deviated from the contractual specification in its inspection and rejection decisions.
4. All of Kestrel's Damages Claims Dismissed in Their Entirety. The Tribunal dismissed each of Kestrel's four categories of claimed damages:
(a) Lost Profits — Remaining Contract Term (€12.83M): Dismissed. The Tribunal found that because WAL's termination was proper, Kestrel had no entitlement to lost profits for the remaining term of the MSA. Additionally, the Tribunal found that lost profits constituted consequential damages barred by the mutual waiver in Section 8.7 of the MSA.
(b) Lost Profits — Renewal Terms (€27.15M): Dismissed. The Tribunal found that the renewal options under the MSA were exercisable solely at WAL's discretion, that no renewal obligation existed, and that Kestrel had no legally cognizable expectation interest in the renewal periods. The Tribunal noted that under New York law, discretionary options do not give rise to expectation damages for the counterparty.
(c) Unreimbursed Rework Costs (€3.42M): Dismissed. The Tribunal found that the rework costs were incurred in connection with Kestrel's attempts to cure non-conforming lots that had been properly rejected, and that under Section 8.4, the costs of cure were borne by the Seller.
(d) Reputational Damages (€3.90M): Dismissed. The Tribunal found that the reputational damages claim was speculative and unsupported by reliable evidence of actual loss. The Tribunal further found that reputational damages fell within the scope of the consequential damages waiver in Section 8.7.
B. Counterclaim Award
The Tribunal sustained WAL's counterclaim in part, awarding WAL €3.82 million. The Tribunal accepted WAL's counterclaim in principle, finding that Kestrel's Persistent Quality Failure caused WAL to incur incremental replacement costs. However, the Tribunal applied a 26% reduction to the claimed amount to account for WAL's duty to mitigate damages, finding that WAL could have sought competitive bids from multiple alternative suppliers more promptly rather than sole-sourcing from Valkyr under time pressure.
The counterclaim arithmetic, as presented in WAL's submissions and adopted by the Tribunal, was as follows:
• Replacement units: 1,680 units
• Valkyr unit price: €8,432.92
• Kestrel CY4 unit price: €5,222.92
• Per-unit differential: €3,210.00
• Gross incremental cost: 1,680 × €3,210.00 = €5,392,800
• Less Valkyr introductory discount (4.2%): €5,392,800 × 0.958 = €5,166,322 ≈ €5.17M
• Less mitigation reduction (26%): €5,170,000 × 0.74 = €3,825,800, rounded by the Tribunal to €3.82M
C. Costs Allocation
The Tribunal ordered the following allocation of costs:
In addition, the Tribunal ordered Kestrel to reimburse WAL $1.85 million of its legal costs, representing a 59.3% recovery of WAL's total claimed legal costs of $3.12 million. The Tribunal noted that while WAL was the substantially prevailing party, a full cost recovery was not warranted given the Tribunal's partial adverse finding on mitigation with respect to the counterclaim.
D. Reserved Jurisdiction
The Partial Award reserved the Tribunal's jurisdiction over two categories of matters: (1) post-award interest calculations on the amounts awarded, and (2) any disputes that may arise regarding the enforcement of the Partial Award. These matters were to be addressed in a Final Award if needed. As of the date of this memorandum, no further proceedings have been initiated, and the matter is closed. Kestrel has not communicated any intention to challenge the Partial Award or to seek its annulment.
VII. FINANCIAL SUMMARY — ENGAGEMENT ECONOMICS
A. Fees and Disbursements
The following table summarizes the total fees and disbursements billed during the engagement:
The costs and disbursements of $634,700 include the following principal categories: expert fees paid to Ridgeline Economic Consulting LLC (Dr. Ostrovsky), Arclight Materials Science Inc. (Dr. Chow), and Canfield & Thorpe LLP (Sandra Gillespie); hearing-related travel and accommodation expenses for attorneys and witnesses; transcript costs for the five-day evidentiary hearing; and WAL's share of the advance on ICC administrative costs and arbitrators' fees.
All invoices were paid by WAL in accordance with the engagement letter's payment terms. No billing disputes arose, and no fee adjustments or write-offs were made during the engagement.
B. Cost Recovery
The Tribunal's cost allocation order requires Kestrel to reimburse WAL $1.85 million of its legal costs. This represents a 59.3% recovery of WAL's total legal spend of $3.12 million. The net unreimbursed legal spend for WAL is therefore:
$3,122,000 (total engagement value) − $1,850,000 (cost reimbursement) = $1,272,000 (net unreimbursed legal spend)
C. Net Financial Outcome for WAL
The overall net financial outcome for WAL from the arbitration is summarized as follows:
The favorable outcome also eliminated any risk to WAL's financial covenant compliance under its $350 million senior secured revolving credit facility with Veltrano National Bank, N.A. An adverse award of the magnitude sought by Kestrel (€47.3 million) would have had significant implications for WAL's financial position and could potentially have triggered covenant compliance issues under the credit facility. The complete dismissal of Kestrel's claims and the favorable counterclaim recovery ensured that no such issues arose.
VIII. LESSONS LEARNED
This section records the key lessons learned from the engagement, both for the benefit of the C&H team and for future reference in similar international arbitration and commercial dispute matters.
A. Importance of Robust Quality Documentation
WAL's meticulous maintenance of incoming inspection records under its quality-control procedure WAL-QCP-100, with detailed lot-by-lot porosity testing documented in accordance with WAL-SPEC-TH-401, Appendix C, Table 3, was the single most important evidentiary pillar supporting WAL's defense. The inspection records provided a clear, contemporaneous, and well-organized documentary trail linking each rejected lot to specific, quantified porosity exceedances. Without this documentation, WAL's defense would have rested far more heavily on retrospective expert analysis, which would have been less persuasive.
Lesson for Future Engagements: Clients in aerospace manufacturing and other industries involving rigorous quality-control standards should be counseled to ensure that their quality-control procedures are rigorously documented, that inspection records are maintained in a manner that permits lot-by-lot analysis, and that rejection notices expressly reference the specific contractual specification thresholds that the non-conforming goods failed to meet. Prospective defense of a termination-for-cause decision is materially strengthened when the terminating party can point to a well-documented, specification-driven quality-control process that operated consistently and transparently throughout the supplier relationship.
B. Contractual Drafting — Exclusive Remedy and Consequential Damages Waivers
The Section 8.7 consequential damages waiver was decisive in eliminating €43.88 million of Kestrel's €47.3 million total claim. The three categories of damages barred by the waiver — lost profits for the remaining term (€12.83M), lost profits for the renewal terms (€27.15M), and reputational damages (€3.90M) — collectively represented approximately 92.8% of Kestrel's total claimed damages. The Tribunal's enforcement of the waiver underscored the importance of clear, well-drafted limitation-of-liability provisions in long-term commercial supply agreements.
Lesson for Future Engagements: Well-drafted consequential damages waivers between sophisticated commercial parties are generally enforceable under New York law and should be a standard feature of long-term supply agreements. Clients should be advised that such waivers provide essential protection against outsized damages claims in the event of a contract dispute. The waiver language should be broad enough to encompass lost profits, lost revenue, loss of use, reputational harm, and other categories of consequential and indirect damages. Where possible, the waiver should be mutual, as a mutual waiver is less susceptible to challenge on grounds of unconscionability or overreaching.
C. Cure Period Amendments — Unintended Consequences
Amendment No. 2's extension of the cure period from thirty to forty-five calendar days — undertaken in response to legitimate COVID-related logistics disruptions — introduced a degree of ambiguity that Kestrel attempted to exploit during the proceedings. Kestrel argued (unsuccessfully) that the extension reflected WAL's recognition that supply-chain difficulties were affecting Kestrel's ability to deliver conforming products and that this recognition should be construed as an implicit relaxation of the quality standards. While this argument was ultimately rejected by the Tribunal, it consumed briefing resources and required careful factual and legal analysis to rebut.
Lesson for Future Engagements: When amending cure periods or other procedural provisions in long-term supply agreements, even in response to exigent circumstances such as a pandemic, the amendment should include explicit language preserving all of the non-amending party's substantive rights, including termination rights. The amendment should clearly state that the extension of the cure period addresses logistics timing and delivery scheduling only and does not modify, relax, or otherwise affect the quality standards, engineering specifications, or acceptance criteria applicable to the goods. A recital in the amendment expressly stating that the parties do not intend the amendment to alter the allocation of quality-related risk would further reduce the potential for misinterpretation.
D. Option vs. Obligation — Renewal Terms
Kestrel's €27.15 million claim for lost profits during the two optional renewal periods was the largest single component of its damages case, representing more than 57% of the total claimed amount. The Tribunal's dismissal of this claim confirmed that discretionary renewal options exercisable at one party's sole discretion do not give rise to expectation damages for the counterparty. This holding is consistent with well-settled principles of New York contract law, but the magnitude of the claim underscores the financial significance of proper contractual drafting.
Lesson for Future Engagements: Contracts should clearly designate renewal options as exercisable at one party's sole discretion, should include express language stating that no renewal obligation exists, and should confirm that the non-exercising party has no expectation interest in any renewal period. Where appropriate, the contract may include a recital stating that the counterparty acknowledges and agrees that the renewal option holder's decision whether to exercise the option is entirely discretionary and that no inference of an obligation to renew may be drawn from the existence of the option or from the parties' conduct during the initial term.
E. Mitigation Duty and Replacement Sourcing
The Tribunal's 26% reduction to WAL's counterclaim — from €5.17 million to €3.82 million — was the only partial adverse finding in the Partial Award and resulted from the Tribunal's determination that WAL failed to adequately mitigate its damages by seeking competitive bids from multiple alternative suppliers more promptly. WAL had sole-sourced its replacement turbine housings from Valkyr Precision Components Inc. due to operational urgency — the quality failures had disrupted WAL's production schedule and threatened its own delivery commitments to downstream customers. While the Tribunal acknowledged the operational pressures WAL faced, it nonetheless found that WAL could have taken more timely steps to solicit competitive proposals from other qualified suppliers.
Lesson for Future Engagements: When terminating a supply relationship and sourcing replacement goods, the client should be advised to document its efforts to obtain competitive bids from multiple alternative suppliers, even if operational urgency strongly favors a single-source solution. The mitigation duty under New York law requires the injured party to take reasonable steps to minimize its losses, and a failure to seek competitive bids may result in a downward adjustment to any damages recovery. Ideally, the client should solicit proposals from at least three alternative suppliers and maintain a contemporaneous record of the solicitation process, the proposals received, the criteria used to evaluate them, and the rationale for selecting the chosen supplier — including any time-pressure or qualification-related factors that limited the field of available alternatives.
F. Expert Selection — Metallurgical Testimony
The Tribunal's decision to credit Dr. Chow's metallurgical analysis over Dr. Kessler's was a significant factor in the outcome. Dr. Chow's credibility was enhanced by several factors: his independence from WAL, his use of industry-standard ASTM testing protocols (specifically ASTM E1441 and ASTM E2371), his laboratory's ISO 17025 accreditation, and his clear and accessible communication style. By contrast, Dr. Kessler's reliance on a non-standard testing protocol that deviated from AS9100 Rev D and ASTM standards undermined the reliability of her conclusions and created a vulnerability that was effectively exploited during cross-examination.
Lesson for Future Engagements: In disputes involving technical quality specifications — particularly in aerospace and defense manufacturing, where adherence to recognized ind